70 related articles for article (PubMed ID: 26045280)
21. NorUDCA promotes degradation of α1-antitrypsin mutant Z protein by inducing autophagy through AMPK/ULK1 pathway.
Tang Y; Blomenkamp KS; Fickert P; Trauner M; Teckman JH
PLoS One; 2018; 13(8):e0200897. PubMed ID: 30067827
[TBL] [Abstract][Full Text] [Related]
22. [Chronic cholestatic liver diseases : Differential diagnosis, pathogenesis and current treatment in adults].
Hohenester S; Beuers U
Internist (Berl); 2017 Aug; 58(8):805-825. PubMed ID: 28721532
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of bile acid mediated inflammation in the liver.
Li M; Cai SY; Boyer JL
Mol Aspects Med; 2017 Aug; 56():45-53. PubMed ID: 28606651
[TBL] [Abstract][Full Text] [Related]
24. Recent advances in understanding and managing cholestasis.
Wagner M; Trauner M
F1000Res; 2016; 5():. PubMed ID: 27134744
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic targets for cholestatic liver injury.
Woolbright BL; Jaeschke H
Expert Opin Ther Targets; 2016; 20(4):463-75. PubMed ID: 26479335
[TBL] [Abstract][Full Text] [Related]
26. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
[TBL] [Abstract][Full Text] [Related]
27. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
Trauner M; Fickert P; Halilbasic E; Moustafa T
Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
[TBL] [Abstract][Full Text] [Related]
28. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
29. Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders.
Trauner M; Halilbasic E; Claudel T; Steinacher D; Fuchs C; Moustafa T; Pollheimer M; Krones E; Kienbacher C; Traussnigg S; Kazemi-Shirazi L; Munda P; Hofer H; Fickert P; Paumgartner G
Dig Dis; 2015; 33(3):433-9. PubMed ID: 26045280
[TBL] [Abstract][Full Text] [Related]
30. Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases.
Halilbasic E; Steinacher D; Trauner M
Dig Dis; 2017; 35(3):288-292. PubMed ID: 28249255
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease.
Steinacher D; Claudel T; Trauner M
Dig Dis; 2017; 35(3):282-287. PubMed ID: 28249257
[TBL] [Abstract][Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
